70 results
POS AM
QNRX
Quoin Pharmaceuticals Ltd
29 Mar 24
Prospectus update (post-effective amendment)
4:11pm
risk minimization tools. Additionally, the manufacturing processes, packaging, distribution, adverse event reporting, labeling, advertising, promotion … commercialization.
Manufacturing of product candidates and conducting required stability testing, product, packaging, equipment and process-related issues may
424B3
QNRX
Quoin Pharmaceuticals Ltd
8 Mar 24
Prospectus supplement
4:06pm
have been in material compliance with all statutes, rules and regulations applicable to the ownership, testing, development, manufacture, packaging
424B3
QNRX
Quoin Pharmaceuticals Ltd
8 Mar 24
Prospectus supplement
4:04pm
applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, advertising, labeling, promotion, sale
8-K
EX-10.1
QNRX
Quoin Pharmaceuticals Ltd
8 Mar 24
Quoin Pharmaceuticals Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies
4:01pm
have been in material compliance with all statutes, rules and regulations applicable to the ownership, testing, development, manufacture, packaging
424B4
l2rpo73 xo0ves
6 Mar 24
Prospectus supplement with pricing info
5:07pm
424B3
ban59wahq8f6cd 19f
4 Mar 24
Prospectus supplement
5:27pm
424B3
m4cx80ntor8w yom
9 Nov 23
Prospectus supplement
5:15pm
424B3
j9wmski dwg5nnsv
14 Sep 23
Prospectus supplement
4:38pm
8-K
EX-10.1
xqkcdnn
12 Sep 23
Entry into a Material Definitive Agreement
6:01pm
DEF 14A
tpj dpt0pg
12 Sep 23
Definitive proxy
6:03am
PRE 14A
5f6srja
1 Sep 23
Preliminary proxy
1:38pm
424B3
o5f k1psnqvbvnsvmx
3 Aug 23
Prospectus supplement
4:51pm
424B3
j7ellhg
9 May 23
Prospectus supplement
4:03pm
10-Q
8haclp tzldzmj
9 May 23
Quarterly report
3:03pm